Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.72 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.67 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.53 |
| ▸ | ECE1 | P42892 | 4/20 | 0.53 |
| ▸ | MME | P08473 | 2/20 | 0.53 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | KYNU | Q16719 | 1/20 | 0.52 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2353879 | 1.00 | ELANE (0.72) | ELANEPRTN3ATMACE2ECE1 | |
| SCHEMBL5076528 | 0.88 | ELANE (0.67) | ELANEPRTN3ATMACE2ECE1 | |
| SCHEMBL5074010 | 0.88 | TACR1 (0.62) | ELANEPRTN3CTSKCTSLCTSB | |
| SCHEMBL8740045 | 0.85 | ELANE (0.60) | ELANEPRTN3ATMACE2ECE1 | |
| SCHEMBL11567174 | 0.85 | ELANE (0.60) | ELANEPRTN3ATMACE2ECE1 | |
| SCHEMBL4163321 | 0.85 | ELANE (0.60) | ELANEPRTN3ATMACE2ECE1 | |
| SCHEMBL6130869 | 0.84 | ELANE (0.63) | ELANEPRTN3ATMACE2ECE1 | |
| SCHEMBL9970972 | 0.84 | ELANE (1.00) | ELANEPRTN3 | |
| SCHEMBL6130888 | 0.82 | ELANE (0.61) | ELANEPRTN3ATMACE2ECE1 | |
| SCHEMBL11033479 | 0.82 | ELANE (0.60) | ELANEPRTN3ECE1MMECTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319366-A1 | Plasma Carboxypeptidase B Inhibitors | BUCKMAN BRAD (US) | 2011-12-29 | — | — | US | disclosed |
| US-8008325-B2 | Plasma carboxypeptidase B inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-08-30 | — | — | US | disclosed |
| EP-2204373-A1 | Phosphonic acid as Plasma Carboxypeptidase B Inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-07-07 | — | — | EP | disclosed |
| US-7528173-B2 | Plasma carboxypeptidase B inhibitors | SCHERING AKTIENGESELLSHAFT (DE) | 2009-05-05 | — | — | US | disclosed |
| US-20090093520-A1 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | BUCKMAN BRAD | 2009-04-09 | — | — | US | disclosed |
| US-20060247213-A1 | Plasma carboxypeptidase b inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-11-02 | — | — | US | disclosed |
| EP-1497300-A2 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | Schering Aktiengesellschaft (DE) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003080631-A2 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319366-A1 | Plasma Carboxypeptidase B Inhibitors | CPB1, CPB2, CPA1 | ELANE 182/4885PRTN3 83/4885ATM 4775/4885 |
| US-20090093520-A1 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | CPB1, CPB2, CPA1 | ELANE 182/4885PRTN3 83/4885ATM 4775/4885 |
| US-20060247213-A1 | Plasma carboxypeptidase b inhibitors | CPB1, CPB2, CPA1 | ELANE 153/4885PRTN3 84/4885ATM 4774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.